THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide

Disclosure: S.L. Samson: Consulting Fee; Self; Novartis Pharmaceuticals, Chiasma. M. Bolanowski: Grant Recipient; Self; Amryt, Recordati, Pfizer, Inc., Novartis Pharmaceuticals, Ipsen, IBSA, Teva Pharmaceutical Industries Ltd., Berlin Chemie. Speaker; Self; Amryt, Recordati, Pfizer, Inc., Novartis P...

Descripción completa

Detalles Bibliográficos
Autores principales: Samson, Susan Leanne, Bolanowski, Marek, Zhang, Shao-Ling, Yu, Yerong, Witek, Przemysław, Kietsiriroje, Noppadol, Piacentini, Andrea, Pedroncelli, Alberto M, Feldt-Rasmussen, Ulla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553625/
http://dx.doi.org/10.1210/jendso/bvad114.1134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553625/
http://dx.doi.org/10.1210/jendso/bvad114.1134

Ejemplares similares